Malin (DUB:MLC) Common Stock: €0.20 Mil (As of Dec. 2024)


What is Malin Common Stock?

Malin DUB:MLC Common Stock is €0.20 Mil as of Dec. 2024.

Malin's quarterly common stock stayed the same from Dec. 2023 (€0.20 Mil) to Jun. 2024 (€0.20 Mil) and stayed the same from Jun. 2024 (€0.20 Mil) to Dec. 2024 (€0.20 Mil).

Malin's annual common stock increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.20 Mil) but then stayed the same from Dec. 2023 (€0.20 Mil) to Dec. 2024 (€0.20 Mil).

Malin Common Stock Historical Data

* Premium members only.

The historical data trend for Malin's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malin Common Stock Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.20 0.20

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.20 0.20 0.20 0.20

Malin Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.20 Mil mean?
Malin (DUB:MLC) has a Common Stock of €0.20 Mil as of Dec. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Malin and its competitors.
Is Malin's Common Stock too high?
Malin's current Common Stock is €0.20 Mil.
How does Malin's Common Stock compare to ZTS and UTHR?
Malin's Common Stock of €0.20 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Malin and its competitors. Malin's current Common Stock is €0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (DUB:MLC) has a current Common Stock of €0.20 Mil. The current Common Stock is €0.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Malin (DUB:MLC), the current Common Stock is €0.20 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.